|Articles|May 1, 2019
- Pharmaceutical Executive-05-01-2019
- Volume 39
- Issue 5
Pharmaceutical Executive, May 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Impact Investing and R&Dover 7 years ago
New Flare-Up in Europe's External Reference Pricing Debateover 7 years ago
It’s Time for a Chief Adherence Officerover 7 years ago
Adopting New Technology: Barriers and Breakthroughsover 7 years ago
The CFO Evolutionover 7 years ago
We’ve Got You Coveredover 7 years ago
Survey Spotlights the CFO’s Strategic Riseover 7 years ago
FDA After Gottlieb: Thorny Issues, Political Challengesover 7 years ago
Easing the Path to Profitabilityover 7 years ago
A Strategic Approach to Pharma R&D Portfolio PlanningAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report
2
Eli Lilly to Acquire Merida Biosciences for $2.8 Billion
3
Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences
4
Simcere Zaiming Licenses Sim0660 to Roche for $1.53 billion
5